Roland "Bud" Henrich, 61, was the first stroke patient to be enrolled in a Phase I trial using his own stem cells.
For the first time in the United States, a stroke patient has been intravenously injected with his own bone marrow stem cells as part of a research trial at The University of Texas Medical School at Houston.
Sean Savitz, M.D., assistant professor of neurology at The University of Texas Medical School at Houston, leads a first-of-its-kind bone marrow stem cell therapy study for stroke patients.
Roland “Bud” Henrich, 61, was transferred to Memorial Hermann – Texas Medical Center on March 25 after suffering a stroke while working on his farm in Liberty. He arrived too late to receive tissue plasminogen activator (tPA), the only treatment for ischemic strokes. He became the first patient in the trial.
The Phase I safety trial, funded with a pilot grant from The National Institutes of Health and support from the Notsew Orm Sands Foundation, will enroll nine more patients who have suffered a stroke and can be treated with the stem cell procedure within 24 to 72 hours of initial symptoms.
Maybe you can find something interesting in the following sponsored links:
